Sudhir Ramchandra Sahasrabudhe PhD
CEO, Prolexys Pharmaceuticals, Inc.
Salt Lake City, UT
Professional summary
I am the scientific founder and CEO of Prolexys Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company’s therapeutic focus is on cancer and cardiovascular indications. We have utilized proteomics-related techniques to identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates. Lead programs include: a) PRLX 93936 small molecule clinical candidate that shows selective lethality towards tumor cells, including those with activated RAS pathway. This compound is currently in Phase I clinical trial. b) the colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.
Specialties and Interests
-
Drug Development,
-
Oncology,
-
Neurology,
-
Proteomics,
-
Biomarkers,
-
Molecular Pharmacology,
-
CNS Diseases,
-
Alzheimer's Disease
Contact
Websites
Education
Universities
MS University
Doctor of Philosophy, research doctorate, Microbiology
Experience
CEO
Member-Board of Associates
Member, Board of Trustees
Member, Board of Directors
Memberships
Publications
Articles
"Interaction of an atypical Plasmodium falciparum ETRAMP with human apolipoproteins."
"RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels."
"Huntingtin interacting proteins are genetic modifiers of neurodegeneration."
"Genome-wide functional analysis of human cell-cycle regulators."
"Initial large-scale exploration of protein-protein interactions in human brain."
"A protein interaction network of the malaria parasite Plasmodium falciparum."
"Phage display of functional human TNF-alpha converting enzyme catalytic domain: a rapid method for the production of stabilized proteolytic proteins for assay development and high-throughput screening."
"Gene expression in lung adenocarcinomas of smokers and nonsmokers."
"A draft sequence of the rice genome (Oryza sativa L. ssp. japonica)."
Disclosure or Conflict of Interest
Sudhir Ramchandra Sahasrabudhe PhD has nothing to disclose
Tokens of Appreciation
- 1 token received
- What are Tokens of Appreciation?
A Token of Appreciation is a way of acknowledging another member for their contributions to Medpedia. You have 5 Tokens to give per week.
